InvivoSciences® Inc.

InvivoSciences® Inc., founded in 2001 and headquartered in the United States, is a trailblazer in the biotechnology sector, with a focus on enhancing drug discovery and life sciences research. With the slogan "Discovery with Human touch," the company innovates in the development of engineered tissue-based assays that mirror the functions of living organisms more accurately than traditional methods.

Their cutting-edge platforms address the limitations of current in vitro drug testing, notably those reliant on two-dimensional (2D) cell cultures. These traditional methods often yield unsatisfactory data, failing to replicate the physical environments in which cells naturally grow. InvivoSciences overcomes these challenges by providing ready-to-use three-dimensional (3D) tissue models, serving as effective alternatives to isolated organ tissue systems and animal models.

The company's commitment to revolutionary solutions is evident in its automated, real-time, high-content platforms that enhance the predictability and cost-effectiveness of drug screening, particularly for cardiac applications. This approach not only reduces the cost and time traditionally associated with animal studies but also delivers high accuracy in assessing new drug toxicities.

Gaining significant recognition, InvivoSciences showcased its technology at the World's Best Technology showcase in Texas in 2009, where it was awarded the prestigious "gold" award after being selected as one of the top 3 by investors and tech-commercialization experts. This accolade was complemented by receiving the 2012 Edison Awards, highlighting their industry impact.

In its most recent funding event, the company secured a Non Equity Assistance investment on 21 October 2020, with backing from MassChallenge. This injection enables the company to further its mission of transforming drug discovery processes globally.